Targeted treatment and immunotherapy of advanced non-small cell lung cancer

Abstract

Non-small cell lung carcinoma (NSCLC) accounts for 85% of all lung cancers. Lung cancer is one of the leading causes of cancer deaths.

Due to targeted therapy and immunotherapy the treatment landscape for locally advanced or metastatic non-small-cell lung cancer has dramatically shifted over the past two decades. Both treatment modalities have significantly improved overall survival for patients with advanced NSCLC.

Keywords

• non-small cell lung cancer
• targeted treatment
• immunotherapy